Johnson & Johnson's fourth-quarter 2015 earnings call presents a positive outlook for the company, despite some short-term challenges. Here are the key points:

1. **Strong Operational Performance**: Johnson & Johnson reported strong underlying operational growth, with sales up 4.4% on an operational basis, and adjusted earnings per share increasing by 5.1% compared to the same period in 2014[4].
2. **Guidance for 2016**: The company provided positive guidance for 2016, expecting operational sales growth of 2.5% to 3.5% and adjusted EPS growth of 5% to 8%, despite ongoing currency headwinds[4].
3. **Margin Expansion**: Johnson & Johnson anticipates significant margin expansion in 2016, driven by cost-saving initiatives and disciplined expense management, which is expected to improve pre-tax operating margins by more than 200 basis points[4].
4. **Innovation and Pipeline**: The company highlighted a robust pipeline in Pharmaceuticals, with several new products expected to launch, including DARZALEX, which has already seen a strong start. The Consumer and Medical Devices segments are also expected to see growth driven by new product launches and improved execution[4].
5. **M&A and Capital Deployment**: Johnson & Johnson has a strong balance sheet and is actively looking for value-creating M&A opportunities, although they remain disciplined in their approach[4].

Given these points, the stock is likely to react positively in the short term due to the strong operational performance, positive guidance, and anticipation of margin expansion.

**Rating: 2**